Skip to main content
SpringerLink
Log in

Oxybutynin Extended Release and Tolterodine Immediate Release

A Health Economic Comparison

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: To evaluate the cost-effectiveness of a new extended-release (XL) formulation of oxybutynin relative to tolterodine immediate release (IR), currently the most prescribed treatment for overactive bladder in the UK.

Methods: A state-transition model was developed to compare outcomes over 1 year. Effectiveness and treatment persistence data were derived from the OBJECT (Overactive Bladder: Judging Effective Control and Treatment) study, a 3-month clinical trial comparing oxybutynin XL 10 mg/day with tolterodine IR 4 mg/day. The daily costs of oxybutynin XL and tolterodine IR were ££0.82 and £1.04, respectively. These data and information from the literature were used to project outcomes beyond the trial time. Severity-specific incontinence cost profiles were developed for the UK (2002 costings).

Results: After 1 year, 3.1 more patients per 100 treated attained complete continence with oxybutynin XL compared with tolterodine IR, and 5.6% more had less than seven incontinent episodes per week. Over 1 year, patients receiving oxybutynin XL had almost 17 additional incontinence-free days and 95 fewer incontinent episodes. Estimated costs were £86 lower per patient with oxybutynin XL. If drugs are priced equally, savings decrease to £21 per patient. Oxybutynin XL maintains its advantage over wide ranges of inputs, and outcomes are similar if analyses are limited to 3 months.

Conclusion: Base-case analyses suggest that oxybutynin XL provides better effectiveness than tolterodine IR and reduces costs. Results indicate that oxybutynin XL is the dominant therapeutic option under a wide range of alternative inputs and assumptions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1
Table III

Similar content being viewed by others

References

  1. Abrams P, Wein AJ. Introduction to the overactive bladder: from basic science to clinical management. Urology 1997; 50Suppl. 6A: 1–3

    Article  Google Scholar 

  2. Abrams P, Blaivas JG, Stanton SL, et al. Standardization of the terminology of lower urinary tract function. Neurourol Urodyn 1988; 7: 403–27

    Article  Google Scholar 

  3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760–6

    Article  PubMed  CAS  Google Scholar 

  4. Roe B, Doll H. Prevalence of urinary incontinence and its relationship with health status. J Clin Nurs 2000; 9: 178–88

    Article  PubMed  CAS  Google Scholar 

  5. Brown JS, Subak LL, Gras J, et al. Urge incontinence: the patient’s perspective. J Womens Health 1998; 7: 1263–9

    Article  PubMed  CAS  Google Scholar 

  6. Temmi C, Haidlinger G, Schmidbauer J, et al. Urinary incontinence in both sexes: prevalence rates and impact on quality of life and sexual life. Neurourol Urodyn 2000; 19: 259–71

    Article  Google Scholar 

  7. Stoddart H, Donavan J, Whitley E, et al. Urinary incontinence in older people in the community: a neglected problem? Br J Gen Pract 2001;51: 548–52

    PubMed  CAS  Google Scholar 

  8. The Continence Foundation. Making the case for investments in an integrated continence service: a sourcebook for continence services (2000). Available from URL: http://www.continence-foundation.org.uk/docs/prageb.htm [Accessed 2002 Aug 18]

  9. Wagner TH, Hu T. Economic costs of urinary incontinence in 1995. Urology 1998; 5193: 356–61

    Google Scholar 

  10. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6(3): 243–62

    Article  PubMed  CAS  Google Scholar 

  11. Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med 2002; 69(10): 761–9

    Article  PubMed  Google Scholar 

  12. Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial for extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc 2001; 76: 358–63

    PubMed  CAS  Google Scholar 

  13. Appell RA, Abrams P, Drutz HP, et al. Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol 2001; 19: 141–7

    Article  PubMed  CAS  Google Scholar 

  14. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001; 18: 551–60

    Article  PubMed  CAS  Google Scholar 

  15. Dmochowski RR, Appell RA. Advancements in pharmacologic management of the overactive bladder. Urology 2000; 56Suppl. 6A: 41–9

    Article  PubMed  CAS  Google Scholar 

  16. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: one-year study. Int Urol Nephrol 2002; 34(1): 43–9

    Article  PubMed  CAS  Google Scholar 

  17. Kobelt G, Jónsson L, Mattiason A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agents: a Markov model. Neurourol Urodyn 1998; 17: 599–611

    Article  PubMed  CAS  Google Scholar 

  18. Kelleher CJ, Cardozo LD, Khullar V, et al. A medium term analysis of the subjective efficacy of treatment for women with detrussor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104: 988–93

    Article  PubMed  CAS  Google Scholar 

  19. Desgagné A, LeLorier J. Incontinence drug utilization patterns in Québec, Canada. Value Health 1999; 2: 452–8

    Article  PubMed  Google Scholar 

  20. Boone TB, Kusek JW, Nyberg LM, et al. Treatment patterns and associated symptom improvement during six months of care for overactive bladder: a prospective, observational study. Clin Ther 2002; 24: 397–408

    Article  PubMed  Google Scholar 

  21. Netten A, Rees T, Harrison G. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent at Canterbury, 2001

  22. Katzman-McClish D, Wyman JF, Sale PG, et al. Use and costs of incontinence pads in female study volunteers: the Continence Program for Women Research Group. J Wound Ostomy Continence Nurs 1999; 26: 207–13

    Google Scholar 

  23. Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997; 50Suppl. 6A: 100–7

    Article  PubMed  CAS  Google Scholar 

  24. Dowell CJ, Bryant CM, Moore KH, et al. Calculating the direct costs of urinary incontinence: a new test instrument. BJU Int 1999; 83: 596–606

    Article  PubMed  CAS  Google Scholar 

  25. Hu T, Wagner TH. Economic considerations for overactive bladder. Am J Manag Care 2000; 6Suppl. 11: S591–8

    PubMed  CAS  Google Scholar 

  26. Wilson L, Brown JS, Shin GP, et al. Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98: 398–406

    Article  PubMed  CAS  Google Scholar 

  27. Arikian SR, Casciano J, Doyle JJ, et al. A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface 2000; 13: 88–94

    PubMed  CAS  Google Scholar 

  28. Cannon T, Chancellor MB. Pharmacotherapy of overactive bladder and advances in drug delivery. Clin Obstet Gynecol 2002; 45: 205–17

    Article  PubMed  Google Scholar 

  29. Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clincal Effectiveness Trial (ACET). Curr Med Res Opin 2002; 18: 177–84

    Article  PubMed  CAS  Google Scholar 

  30. Noe L, Becker R, Williamson T, et al. A pharmacoeconomic model comparing two long-acting treatments for overactive bladder. J Manag Care Pharm 2002; 8: 343–52

    PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by a grant from Janssen Pharmaceutica, where authors W. Feng and D. Dubois are employed, to Caro Research, where authors D. Getsios, J. Caro, K. Ishak, W. El-Hadi, and K. Payne are employed and of which J. Caro is a shareholder. Caro Research has also received grants for unrelated research from Pfizer, the makers of products potentially affected by this work. Authors M. O’Connel and D. Albrecht are employees of ALZA Corporation. The sponsor collaborated in helping set the specifications for the model and by providing data on the OBJECT trial, but had no role in methodological decisions or interpretation of results. The sponsor was allowed to review and comment on this manuscript but was explicitly forbidden from exerting any editorial control.

Author information

Authors and Affiliations

  1. Caro Research Institute, Hammonds Plains, Nova Scotia, Canada

    D. Getsios

  2. Caro Research Institute, 336 Baker Avenue, Concord, Massachusetts, 01742, USA

    J. J. Caro

  3. Division of General Internal Medicine, Royal Victoria Hospital, McGill University, Contreal, Quebec, Canada

    J. J. Caro

  4. Caro Research Institute, Montreal, Quebec, Canada

    K. J. Ishak, W. El-Hadi & K. Payne

  5. ALZA Corporation, Mountain View, California, USA

    M. O’Connel & D. Albrecht

  6. Johnson & Johnson PGSM, Raritan, New Jersey, USA

    W. Feng

  7. Janssen Pharmaceutica NV, Beerse, Belgium

    D. Dubois

Authors
  1. D. Getsios
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. J. Caro
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. J. Ishak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. El-Hadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K. Payne
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. O’Connel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D. Albrecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W. Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. D. Dubois
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. J. Caro.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Getsios, D., Caro, J.J., Ishak, K.J. et al. Oxybutynin Extended Release and Tolterodine Immediate Release. Clin. Drug Investig. 24, 81–88 (2004). https://doi.org/10.2165/00044011-200424020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200424020-00003

Keywords

Search

Navigation